NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 12 August 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Arpit Srivastava Present for all items
4. Dr Clare Offer Present for all items
5. Dr David Foreman Present for all items
6. Dawn Cooper Present for all items
7. Elizabeth Thurgar Present for items 5.1 to 5.2.2
8. John Hampson Present for all items
9. Dr Jonathan Sive Present for all items
10. Dr Kate Ren Present for all items
11. Louise Hunt Present for all items
12. Dr Mark Corbett Present for all items
13. Michael Chambers Present for all items
14. Dr Pedro Saramago Goncalves Present for all items
15. Dr Prithwiraj Das Present for all items
16. Richard Boldero Present for all items
17. Stella O’Brien Present for all items
18. Ugochi Nwulu Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Items 4.1 to 5.2.2

Leena Issa, Project Manager Items 4.1 to 5.2.2

Alex Filby, Heath Technology Assessment Adviser Items 4.1 to 4.2.2

Zain Hussain, Heath Technology Assessment Analyst Items 4.1 to 4.2.2

Ellie Donegan, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Amy Grove, Birmingham Centre for Evidence and Implementation Science Items 4.1 to 4.1.3

Peter Auguste, Birmingham Centre for Evidence and Implementation Science Items 4.1 to 4.1.3

Dawn Lee, Peninsula Technology Assessment Group Items 5.1 to 5.1.3

Maxwell Barnish, Peninsula Technology Assessment Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Neil Rabin, Consultant Haematologist, clinical expert nominated by Johnson & Johnson Innovative Medicine Items 4.1 to 4.1.3

Dr Sarah Lawless, Consultant Haematologist, clinical expert nominated by the UK Myeloma Society Items 4.1 to 4.1.3

Caroline Donoghue, Access Manager (Policy), Myeloma UK, patient expert nominated by Myeloma UK Items 4.1 to 4.1.3

Sue Harley, patient expert nominated by Myeloma UK Items 4.1 to 4.1.3

James Richardson, National Specialty Advisor (Cancer Drugs), commissioning expert Items 4.1 to 4.1.3

Dr Scott Hackett, Consultant Paediatric Immunologist, clinical expert nominated by NHS England Items 5.1 to 5.1.3

Dr Sorena Kiani-Alikhan, Consultant Immunologist, clinical expert nominated by Takeda UK Items 5.1 to 5.1.3

Angela Metcalfe, Chief Executive Officer, HAE UK, patient expert nominated by HAE UK Items 5.1 to 5.1.3

Dr Tim Crouch, HAE UK Trustee,patient expert nominated by HAE UK Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Professor Stephen O’Brien, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Alex Cale, Professor Andrew Renehan, Iain McGowan, and Satish Venkateshan.

### News and announcements

* 1. The chair informed the committee that Andrew Renehan will be stepping down from committee after today’s meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 8th July 2025.

### Appraisal of Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Johnson & Johnson Innovative Medicine.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10969).
     3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Mark Corbett and Stella O’Brien.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta10969) in due course.

### Appraisal of Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

* 1. Part 1 – Open session
     1. The vice-chair, Dr Richard Nicholas, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from CSL Behring.
     2. The vice-chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11452).
     3. The vice-chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the vice-chair.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11452) in due course.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 9th September and will start promptly at 9am.